Clinical trials: Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms
Prostate Carcinoma, Benign Prostatic Hyperplasia
Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization
This is a Phase II prospective clinical trial in which patients with prostate carcinoma and obstructive lower urinary tract symptoms electing for radiation therapy will undergo Prostatic Artery Embolization (PAE) prior to…
- Trial name
- NCT04879940
- Testing
- Merit Medical Embospheres, Radiation Therapy
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Nonmalignant Neoplasm, Prostate Cancer
Pelvic Floor Muscle Training and Biofeedback or Standard Therapy in Men Who Have Undergone Radical Prostatectomy or Transurethral Resection of the Prostate
RATIONALE: Personalized training by a health professional may improve urinary incontinence. It is not yet known whether pelvic floor muscle training and biofeedback are more effective than standard therapy in improving urinary…
- Conditions
- Nonmalignant Neoplasm, Prostate Cancer, Psychosocial Effects of Cancer and Its Treatment, Sexual Dysfunction
- Trial name
- NCT00632138
- Testing
- exercise intervention, questionnaire administration, biofeedback
- Where
- 37 sites in United Kingdom
- Volunteers
- 800 people
- Sponsor
- Aberdeen Royal Infirmary
Impotence
Effectiveness and Safety of Viagra in Men With ED and LUTS Due to Benign Prostatic Hyperplasia (BPH)
The purpose of this study is to determine whether Viagra is effective in treating erectile dysfunction and lower urinary tract symptoms in men affected by both conditions.
- Trial name
- NCT00143221
- Testing
- Viagra
- Volunteers
- 350 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Effect of Different Dosing Regimens of Tadalafil or Tamsulosin Combined With 5α-Reductase Inhibitors on Urinary and Sexual Outcomes in Benign Prostatic Hyperplasia
Benign prostatic hyperplasia (BPH) is a common condition among aging men that causes lower urinary tract symptoms (LUTS) and may negatively affect sexual function.
- Conditions
- Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms, Erectile Dysfunction
- Trial name
- DTT-BPH (NCT07715448)
- Testing
- Tamsulosin, Tadalafil, 5-Alpha Reductase Inhibitor
- Where
- Egypt
- Volunteers
- 240 people
- Sponsor
- Beni-Suef University
Prostatic Hyperplasia, Benign
Efficacy/ Safety of Product DNN.65.21.005 in Patients With Benign Prostatic Hyperplasia
To evaluate the safety and efficacy of DNN.65.21.005 versus Combodart® in the treatment of benign prostatic hyperplasia
- Trial name
- NICCOLO (NCT07270432)
- Testing
- Product DNN.65.21.005, Combodart®
- Volunteers
- 218 people
- Sponsor
- Ache Laboratorios Farmaceuticos S.A.
Benign Prostatic Hyperplasia (BPH)
A Trial to Investigate the Effectiveness and Safety of Org 3236 (Etonogestrel) Tablets in Men With Urinary Complaints Suggestive of a Benign Enlargement of the Prostate (304001)(P05806)
This trial is conducted to evaluate the effect of etonogestrel in comparison to placebo on: the prostate volume and the urinary complaints; the urinary flow and the urinary volume in the bladder after voiding; the progression of…
- Trial name
- NCT00651807
- Testing
- etonogestrel
- Where
- Argentina
- Volunteers
- 16 people
- Sponsor
- Organon and Co
Lower Urinary Tract Symptoms
Effect of Enhanced External Counterpulsation on Lower Urinary Tract Symptoms
The purpose of this study is to access the effects of Enhanced External Counterpulsation treatment on lower urinary tract symptoms in patients with benign prostatic hyperplasia.
- Trial name
- EECPLUTS (NCT01815697)
- Testing
- Enhanced External Counterpulsation
- Where
- China
- Volunteers
- 120 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Nocturia, Benign Prostatic Hyperplasia
Efficacy and Safety of Silodosin on Nocturia for Patients With Benign Prostatic Hyperplasia
The objective of this study is to determine safety and efficacy of silodosin, which is a treatment for benign prostatic hyperplasia with high selectivity to α1A-receptor, on patients with benign prostatic hyperplasia accompanied…
- Trial name
- BPH (NCT02106182)
- Testing
- Silodosin, Laboratory tests, 3-days voiding diary
- Where
- 6 sites in South Korea
- Volunteers
- 135 people
- Sponsor
- JW Pharmaceutical
Benign Prostatic Hyperplasia, Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms
Feasibility and Utility of a Prehabilitation Program for Use in Patients With Benign Prostatic Hyperplasia Who Have Elected to Undergo Holmium Laser Enucleation of the Prostate (HoLEP).
Benign prostatic hyperplasia (BPH) is a debilitating condition which is highly prevalent in older males, up to 45% of those over the age of 45 are affected and 80% of those over the age of 70 are affected.
- Conditions
- Benign Prostatic Hyperplasia, Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia With Outflow Obstruction
- Trial name
- NCT07552961
- Testing
- Comprehensive Prehabilitation Programming
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- University of Calgary
Overactive Bladder
Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)
This study will assess the efficacy of vibegron compared with placebo in men with overactive bladder (OAB) symptoms on pharmacological therapy for benign prostatic hyperplasia (BPH) as defined by micturition and urgency episodes.
- Trial name
- NCT03902080
- Testing
- Vibegron
- Where
- 140 sites in United States, Belgium and 6 more
- Volunteers
- 1,105 people
- Sponsor
- Urovant Sciences GmbH
Overactive Bladder
A Phase 4 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects With Overactive Bladder (OAB) Symptoms, While Taking the Alpha Blocker for Benign Prostatic Hypertrophy (BPH)
The primary objective of the study was to investigate the efficacy of mirabegron versus placebo in male patients with OAB symptoms while taking the alpha blocker, tamsulosin, for BPH.
- Trial name
- NCT02656173
- Testing
- Mirabegron, Tamsulosin
- Where
- 58 sites in Japan, South Korea
- Volunteers
- 568 people
- Sponsor
- Astellas Pharma Inc
Lower Urinary Tract Symptoms, Prostatic Hyperplasia
Efficacy and Safety of Longidaze in the Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia
The goal of this clinical trial is to learn if Longidaze works to treat lower urinary tract symptoms in adult males with benign prostatic hyperplasia. It will also learn about the safety of Longidaze.
- Trial name
- ADAM (NCT06568718)
- Testing
- bovhyaluronidase azoximer, tamsulosin
- Where
- 3 sites in Russia
- Volunteers
- 229 people
- Sponsor
- NPO Petrovax
Benign Prostatic Hyperplasia
Α Prospective Observational Study for the Evaluation of Disease Control and Quality of Life in Patients With Benign PROStatic hyPERplasia Under Fixed Dose combΙnaTion Treatment With Dutasteride and Tamsulosin . PROSPERITY Group of Studies (I&II)
Investigation of the efficacy and safety of the stable combination of dutasteride and tamsulosin (Dinaplex®) in the Greek population as well as the evaluation of the quality of life of patients with benign prostatic hyperplasia…
- Trial name
- PROSPERITY (NCT04831476)
- Testing
- Patients with Benign Prostate Hyperplasia
- Where
- Greece
- Volunteers
- 1,296 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Benign Prostatic Hyperplasia
(Phosphodiesterase 5 Inhibitors & α-blockers): Single Versus Combined Therapy in Benign Prostatic Hyperplasia
To compare between efficacy of phosphodiesterase5 inhibitors (tadalafil 5 mg) and Alpha Blockers (tamsulosin 0.4 mg) monotherapy vs combined therapy in treatment of lower urinary tract symptoms of benign prostatic hyperplasia.
- Trial name
- NCT05236634
- Testing
- Phosphodiesterase 5 Inhibitors, Alpha Blockers, Combined Alpha Blockers and Phosphodiesterase 5 Inhibitors
- Volunteers
- 120 people
- Sponsor
- Assiut University
Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia
Clinical Trial to Evaluate the Efficacy and Safety of Naftopidil in Male Patients With Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia
This study is designed to evaluate the efficacy and safety of Naftopidil in Korean male patients with with lower urinary tract symptoms associated with benign prostatic hyperplasia.
- Trial name
- NCT01922375
- Testing
- Naftopidil
- Where
- South Korea
- Volunteers
- 411 people
- Sponsor
- Dong-A Pharmaceutical Co., Ltd.
Overactive Bladder, Benign Prostatic Hyperplasia
Combination Treatment With Doxazosin Plus TolterodineSR 2 mg Versus 4mg in Men With an Overactive Bladder (OAB) and Benign Prostatic Hyperplasia (BPH)
OAB occurs in approximately 50% to 75% of men with BPO and up to 38% of men with BPO continue to suffer from OAB after relief the obstruction.Symptoms of OAB are more bothersome than the voiding complaints of slow stream and…
- Trial name
- NCT00922506
- Testing
- doxazosin plus tolterodine SR
- Where
- South Korea
- Volunteers
- 83 people
- Sponsor
- Samsung Medical Center
Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Study of Solifenacin Succinate and Tamsulosin Hydrochloride OCAS in Males With Lower Urinary Tract Symptoms
Clinical study to examine the efficacy, safety and tolerability of combination therapy of tamsulosin hydrochloride and solifenacin succinate compared to monotherapy of tamsulosin hydrochloride in the treatment of males with LUTS…
- Trial name
- Neptune (NCT01018511)
- Testing
- tamsulosin hydrochloride OCAS 0.4 mg, tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg)
- Where
- 118 sites in Austria, Belarus and 11 more
- Volunteers
- 1,334 people
- Sponsor
- Astellas Pharma Europe B.V.
Safety, Efficacy
Tamsulosin Monotherapy Versus Combination Therapy With Tadalafil (2.5 mg vs 5 mg) in Managing Male LUTS Secondary to BPH
This study aims to evaluate the short-term impact and clinical outcomes of tamsulosin monotherapy versus combination therapy with tamsulosin plus tadalafil (2.5 mg vs.
- Conditions
- Safety, Efficacy, Tamsulosin, Monotherapy
- Trial name
- NCT07722884
- Testing
- Tamsulosin 0.4 mg + Tadalafil 2.5 mg, Tamsulosin 0.4 mg + Tadalafil 5 mg, Tamsulosin 0.4 mg
- Where
- Egypt
- Volunteers
- 90 people
- Sponsor
- Ain Shams University
Benign Prostate Hyperplasia
Advanced Benefits of Alpha-blocker Monotherapy on Lower Urinary Tracts Symptoms(LUTS) Patients
The purpose of this study is to evaluate the clinical efficacy of alpha-blocker monotherapy and alpha-blocker + 5-alpha reductase inhibitor combination therapy in benign prostate hyperplasia patients, and suggest guidelines of…
- Trial name
- ABSOLUTE (NCT01736033)
- Testing
- Tamsulosin, Finasteride
- Where
- 11 sites in South Korea
- Volunteers
- 545 people
- Sponsor
- Seoul National University Hospital
Overactive Bladder Syndrome, Bladder Outlet Obstruction
Urodynamics and Clinical Factors That Are Associated With Bladder Over-sensitivity
Urodynamic examination evaluates storage and empting phases of the urinary bladder. It enables the clinician to correlate physiologic findings to patients' complains.
- Conditions
- Overactive Bladder Syndrome, Bladder Outlet Obstruction, Benign Prostate Enlargement, Stress Incontinence (Female) (Male)
- Trial name
- NCT03486639
- Testing
- IPSS questionnaire
- Where
- Israel
- Volunteers
- 330 people
- Sponsor
- Assaf-Harofeh Medical Center